Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Shares Repurchased (2016 - 2025)

Cryo Cell International (CCEL) has disclosed Shares Repurchased for 11 consecutive years, with $80883.0 as the latest value for Q3 2025.

  • On a quarterly basis, Shares Repurchased rose 393.19% to $80883.0 in Q3 2025 year-over-year; TTM through Nov 2025 was $169502.0, a 88.1% decrease, with the full-year FY2025 number at $169502.0, down 88.1% from a year prior.
  • Shares Repurchased was $80883.0 for Q3 2025 at Cryo Cell International, down from $88619.0 in the prior quarter.
  • In the past five years, Shares Repurchased ranged from a high of $1.2 million in Q2 2024 to a low of $7584.0 in Q3 2023.
  • A 5-year average of $343207.8 and a median of $243201.0 in 2023 define the central range for Shares Repurchased.
  • Peak YoY movement for Shares Repurchased: crashed 97.16% in 2023, then surged 393.19% in 2025.
  • Cryo Cell International's Shares Repurchased stood at $249377.0 in 2021, then crashed by 48.88% to $127482.0 in 2022, then plummeted by 94.05% to $7584.0 in 2023, then skyrocketed by 116.24% to $16400.0 in 2024, then soared by 393.19% to $80883.0 in 2025.
  • Per Business Quant, the three most recent readings for CCEL's Shares Repurchased are $80883.0 (Q3 2025), $88619.0 (Q2 2025), and $16400.0 (Q3 2024).